MTAC Trademark

Trademark Overview

On Monday, February 27, 2023, a trademark application was filed for MTAC with the United States Patent and Trademark Office. The USPTO has given the MTAC trademark a serial number of 97813153. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, May 20, 2025. This trademark is owned by Avilar Therapeutics, Inc.. The MTAC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of pharmaceutical preparations that bind to mannose 6-phosphate (M6P) receptors
mtac

General Information

Serial Number97813153
Word MarkMTAC
Filing DateMonday, February 27, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, May 20, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 20, 2025

Trademark Statements

Goods and ServicesResearch and development in the field of pharmaceutical preparations that bind to mannose 6-phosphate (M6P) receptors

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, March 18, 2023
Primary Code042
First Use Anywhere DateSaturday, May 4, 2024
First Use In Commerce DateSaturday, May 4, 2024

Trademark Owner History

Party NameAvilar Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameAvilar Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Thursday, March 2, 2023NEW APPLICATION ENTERED
Thursday, November 30, 2023NON-FINAL ACTION E-MAILED
Saturday, March 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 28, 2023ASSIGNED TO EXAMINER
Thursday, November 30, 2023NON-FINAL ACTION WRITTEN
Thursday, November 30, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 26, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, February 26, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, May 6, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 6, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 6, 2024USE AMENDMENT FILED
Monday, May 6, 2024TEAS AMENDMENT OF USE RECEIVED
Monday, May 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 18, 2024AMENDMENT TO USE PROCESSING COMPLETE
Wednesday, September 18, 2024ASSIGNED TO LIE
Thursday, September 19, 2024USE AMENDMENT ACCEPTED
Thursday, September 19, 2024NON-FINAL ACTION WRITTEN
Thursday, September 19, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 19, 2024NON-FINAL ACTION E-MAILED
Tuesday, December 17, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, December 17, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, March 10, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 10, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 10, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, April 19, 2025ALLEGED AMENDMENT TO USE WITHDRAWN
Saturday, April 19, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 14, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 20, 2025PUBLISHED FOR OPPOSITION
Tuesday, May 20, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

mtac mannose phosphate receptors bind preparations development field pharmaceutical research